The European Commission approved Samsung Biologics (KRX:207940) subsidiary Samsung Bioepis' and US-based biotechnology company Biogen's biosimilar Opuviz, or SB15, for treating various vision-related conditions, including wet AMD and diabetic macular edema.
Clinical trials confirmed SB15's equivalent efficacy, safety, and pharmacokinetics to reference Eylea, or aflibercept. Opuviz is Samsung Bioepis' second ophthalmology biosimilar in Europe and part of its growing biosimilar portfolio, Samsung Bioepis said earlier this week.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments